Jefferies Group’s 10x Genomics TXG Stock Holding History

Jefferies Group’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-667	Closed	-$60	–	1551
2020 Q2	$60	Buy	+667	New	+$52K	﹤0.01%	1147

Other funds holding TXG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jefferies Group's TXG Position: Q3 2020 in Review

Jefferies Group sold out of 10x Genomics (TXG) in Q3 2020, closing a stake of 667 shares — an estimated $60 sold.

Jefferies Group first reported a position in TXG in Q2 2020 and held it in 1 quarter. The position peaked at $60 in Q2 2020. 218 funds tracked by Wall St. Rank hold TXG as of Q3 2020.

Jefferies Group reported no remaining 10x Genomics position as of Q3 2020 after selling out during the quarter.
Jefferies Group sold 667 10x Genomics shares in Q3 2020, an estimated $60.
Jefferies Group first reported a position in 10x Genomics in Q2 2020 and held it in 1 quarter.
Jefferies Group's 10x Genomics position peaked at $60 in Q2 2020.
218 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2020.

Based on Jefferies Group's 13F filing for Q3 2020, filed 13 Nov 2020.